Wenglian Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a multi-route veterinary active pharmaceutical ingredient. The trade descriptor functions as the model identifier in batch documentation; no separate numeric model designation is assigned in the manufacturer’s current technical file. The substance is specified for use in direct-compression tablets, wet-granulated granules, powder-filled hard capsules, in-feed premixes, and terminally sterilized or aseptically filtered injection solutions. The grade is controlled for particle size distribution, bulk and tapped density, related substances, residual solvents, elemental impurities, non-sterile microbial quality, and bacterial endotoxins when the parenteral route is requested. Release testing is aligned with the general methods of the European Pharmacopoeia, including Ph. Eur. 2.2.20 for assay by liquid chromatography, Ph. Eur. 2.2.29 for related substances, Ph. Eur. 2.2.32 for loss on drying, Ph. Eur. 2.4.16 for residue on ignition, Ph. Eur. 2.9.31 for particle size by laser diffraction, Ph. Eur. 2.9.34 for bulk and tapped density, Ph. Eur. 2.9.36 for powder flow, Ph. Eur. 5.1.4 for microbial limits in non-sterile substances, and Ph. Eur. 2.6.14 for bacterial endotoxins in injection-grade material.

The release platform is method-defined rather than fixed across every dosage route. Representative compendial acceptance criteria for veterinary APIs in this category include an assay range of 98.0–102.0% on the dried basis, total related substances not more than 1.0%, loss on drying not more than 1.0%, and residue on ignition not more than 0.1%. These values are general monograph ceilings, not batch-specific guarantees. The certificate of analysis issued by the manufacturing quality unit remains the controlling document. Product-specific release limits should be confirmed before formulation because residual solvent class and elemental impurity thresholds depend on the synthetic route and the target species.

Handling boundary: the API should be brought to 20–25 °C before container opening if stored under refrigeration. If ambient relative humidity exceeds 60%, the material should be dispensed in a low-humidity suite and the container reclosed within 30 min to avoid moisture uptake. Avoid combination with strongly acidic excipients unless the formulation is designed as a stable salt. These operational controls preserve flow properties, assay, and powder handling characteristics during multi-route formulation.

What Physicochemical Attributes Are Controlled for Multi-Route Veterinary Processing?

Particle size distribution is the central control parameter for multi-route performance. Laser diffraction by Ph. Eur. 2.9.31 reports D10, D50, and D90 values. Dry blending and direct compression require a volume mean diameter large enough to maintain flow, while injection and oral solution processing require a surface area high enough to permit dissolution or suspension wetting. A single distribution cannot simultaneously maximize flow and dissolution rate; therefore, the grade is provided with a controlled central distribution and the manufacturer recommends route-specific mechanical treatment before terminal stages. For example, dry granulation slugs or tablets may be produced from material with a D90 above 100 µm, whereas sterile injection preparation after reconstitution typically uses a separate micronized or spray-dried fraction with a D90 below 10 µm to ensure syringeability and filter passage.

Acceptance criteria are not identical across all routes. An injection-grade batch may have tighter endotoxin and particulate matter specifications, while a premix-grade batch may allow a slightly broader particle size distribution if a wet granulation or carrier blend step follows. The manufacturer’s batch dossier should be consulted before route substitution.

Dry compression of the direct-compression grade on an instrumented rotary tablet press is performed at main compression force between 8 kN and 12 kN for a 200 mg core weight containing 10% w/w active ingredient. The powder blend contains microcrystalline cellulose and croscarmellose sodium; magnesium stearate is added at 0.5% w/w after pre-lubrication blending. Weight variation is assessed by Ph. Eur. 2.9.5, and friability is assessed by Ph. Eur. 2.9.7. A friability result below 1.0% and a disintegration time below 15 min by Ph. Eur. 2.9.1 are common development targets for immediate-release tablets, but the finished formulation must establish these values; the API itself does not impose them.

Wet granulation in a top-spray fluid-bed granulator uses inlet air temperature between 40 °C and 60 °C and a spray rate adjusted to maintain product temperature below 40 °C. The binder solution, typically povidone K30 at 3–5% w/w of dry mass, is sprayed after a 3 min dry-mix step. Granulation endpoint is determined by pressure drop and filter bag pressure differential, not by fixed time only. Dried granules are size-reduced through a 1.0 mm screen and blended with disintegrant. Batch-to-batch variation in granule bulk density should be monitored by Ph. Eur. 2.9.34; a shift above 5% relative standard deviation in bulk density across sub-lots signals heterogeneity in the API distribution.

When Sterile Injection or Aqueous Solution Processing Is Required

The injection route imposes additional controls that are not relevant to oral powders or premixes. The API is dissolved in Water for Injection or a buffered isotonic vehicle at a concentration derived from the target species dose. The solution is clarified through a 0.22 µm polyvinylidene fluoride or polyether sulfone membrane filter; the membrane is selected on the basis of drug adsorption data, not solely pore size. If terminal sterilization is used, a typical cycle is 121 °C for 15 min. This cycle is acceptable only if forced-degradation studies at the sterilization temperature demonstrate no new related substance above the identification threshold described in Ph. Eur. 2.2.29 or ICH Q3B. For thermolabile formulations, aseptic filtration and sterile filling replace terminal heat; in that case the pre-filtration bioburden is limited by Ph. Eur. 5.1.4 and the sterile filtrate is held only for a validated hold time.

Bacterial endotoxin control is performed by Ph. Eur. 2.6.14. The limit is not fixed by the API supplier; it is derived from the maximum intended veterinary dose, body weight, and the endotoxin limit for the species. A common parenteral threshold is 5 EU/kg body weight per hour for large animals, but species-specific deviation and regulatory guidance apply. The solution pH is measured by Ph. Eur. 2.2.3, and the osmolality by Ph. Eur. 2.2.35. Precipitation during pH adjustment indicates that a salt form or co-solvent system should be redesigned; the API grade does not eliminate solubility equilibrium constraints.

Capsule Fill, Premix Homogeneity, and Feed Integration Limits

Hard capsule filling with the powder grade depends on bulk density and flow stability. Tamped filling machines require a Hausner ratio below 1.25 for consistent fill weight; dosator machines can tolerate higher ratios if the powder is precompressed. Bulk density by Ph. Eur. 2.9.34 is reported on the certificate of analysis to support fill weight calculation. For capsule formulations containing 20 mg to 200 mg active per capsule, content uniformity is evaluated by Ph. Eur. 2.9.40. A fill weight variation below 3% relative standard deviation is a typical development target, but the official acceptance value remains the pharmacopoeial AV limit.

For in-feed premixes, the API is geometrically diluted with lactose monohydrate, dextrose, or a defined carrier. Mixing uniformity is measured by Ph. Eur. 2.9.40 or equivalent in-process sampling after discharge from the ribbon blender. The major segregation risk is not the API assay but particle size ratio; if the D90 of the API exceeds the carrier D50 by more than 10-fold, vibration during transport can de-mix the blend. The multi-route grade is therefore supplied with a particle size distribution that can be matched to the carrier. Final feed premix inclusion is typically 1 kg/tonne to 10 kg/tonne depending on the active potency and target species; the conversion from API to premix must be verified by recovery studies using Ph. Eur. 2.2.20 or a species-specific HPLC method.

In oral powders and granules, the API is either dry-blended or granulated to form a suspending or direct administration powder. The granule fraction is sieved to 0.5–1.25 mm to ensure uniform dispersion in drinking water if the product is water-soluble. Dissolution performance of granules in water at 25 °C can be screened by a simple sink-condition test, but no pharmacopoeial dissolution method applies to all veterinary premises; published data for this specific configuration is limited.

Multi-Route Polymorph Control Is Not Equivalent to Single-Route Supply

The main distinction from conventional single-route veterinary APIs is the consolidated control of particle size, polymorphic form, and microbial quality across multiple dosage forms. A conventional material supplied for tablet manufacture may be unmilled crystalline substance with a broad particle size range and no parenteral-grade documentation. When used in an injectable or in-feed formulation, that material often requires additional micronization, terminal filtration, or extended mixing to meet the same process window. The Wenglian grade is not a single particle size product; it is a controlled-platform material intended to reduce the number of upstream unit operations and the variability they introduce.

Published data for this specific trade configuration is limited. Comparative qualification against an incumbent single-route API should include identical analytical methods, not merely summary certificate values. Otherwise differences in particle size method settings can create apparent material differences that are not pharmaceutically relevant.